Targeting ADAMS and ERBBs in lung cancer.

@article{Hynes2006TargetingAA,
  title={Targeting ADAMS and ERBBs in lung cancer.},
  author={Nancy E. Hynes and Thomas Schlange},
  journal={Cancer cell},
  year={2006},
  volume={10 1},
  pages={
          7-11
        }
}
Aberrant ERBB receptor activity contributes to the development of many human cancers. Receptor overexpression, kinase domain (KD) mutations, and autocrine ligand production contribute to ERBB activation in human tumors. ERBB-targeted tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are used in cancer treatment; however, clinical hurdles, including patient selection and TKI resistance, need to be overcome in order to optimize therapy. This minireview will discuss recent findings on… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  • Resistance to Targeted Anti-Cancer Therapeutics
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Amphiregulin Promotes Vascular Endothelial Growth Factor-C Expression and Lymphangiogenesis through STAT3 Activation in Human Chondrosarcoma Cells.

  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • 2019

Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

Role of ADAMs in cancer formation and progression.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2009